Product Images Aripiprazole

Safecor Health provides unit dose packages of Aripiprazole that meet USP specifications for light resistance. Each tablet contains 10 mg of Aripiprazole and the usual adult dosage is listed on the package insert. The package is not child resistant and is intended for institutional use only. The medication should be stored at 20° - 25°C (68° - 77°F) and kept out of the reach of children. The lot number is 956633 and the medication is manufactured by Apotex Inc. for Apotex Corp. The package includes 100 unit dose blisters and is distributed by Safecor Health, LLC.*

The text describes a package of 100 unit doses of Aripiprazole tablets containing 15mg each. The package is designed for institutional use only, is not child-resistant, and meets USP specifications for light resistance. The tablets must be stored between 20°C-25°C with excursions permitted to 15°C-30°C. The usual adult dosage information is on the package insert, and the product is Rx only with the NDC number 48433-118-10 and lot number 956633. The manufacturer is Apotex Inc., Toronto, ONT MOL1T9, Canada, and produced for Apotex Corp., Weston, FLA 33326, referring to the NDC number 60505-2675. The company responsible for packaging and distribution is Safecor Health, LLC.*

This is a description of a prescription medication called Aripiprazole. The tablet comes in a 20 mg dose and is packaged in unit dose blisters that meet USP specifications for light resistance. The packaging design is not child-resistant and is intended for institutional use only. The medication should be stored between 20° - 25°C (68° - 77°F) with excursions permitted to 15° - 30°C (59° - 86°F). The medication is only available with a prescription and the usual adult dosage instructions can be found in the package insert. The medication is manufactured in Canada by Apotex Inc. for Apotex Corp. and distributed by Safecor Health LLC in the USA. The packaging contains 100 unit dose blisters, and the NDC number is 48433-119-01. *

This is a package of Aripiprazole 2 mg Tablets, each containing 2 mg of the medication. The package contains 100 unit dose blisters, which is for institutional use only. The tablets should be stored at a controlled room temperature between 20°C-25°C (68°F-77°F) with excursions permitted to 15°C-30°C (59°F-86°F). The usual adult dosage is not provided and must refer to package insert. The package is not child resistant, so it must be kept out of reach of children. The lot number is 956633 and the NDC is 48433-115-10. The manufacturer is Apotex Inc. from Canada, and Safecor Health, LLC packaged & distributed it from Woburn, MA 01801 USA.*

This is a description of a medication packaging produced by Safecor Health that contains 100 unit dose blisters of Aripiprazole tablets. Each tablet contains 30mg of the medication. The package design does not include child-resistant features and is intended for institutional use only. The package meets USP specifications for light resistance. The recommended storage conditions are between 20-25°C (68-77°F) with permissible excursions permitted between 15-30°C (59-86°F). The medication is distributed under NDC 48433-120-10 and the lot number 956633. The usual adult dosage is not mentioned, and further information can be found in the package insert. The product was manufactured by Apotex Inc. in Canada and mfg for Apotex Corp. in Weston, FL with references to NDC 60505-2677. The packaging was distributed by Safecor Health, LLC located in Massachusetts, USA.*

The text describes unit dose packages of tablets containing 5 mg of Aripiprazole, which are not child-resistant and meant for institutional use only. The tablets meet USP specifications for light resistance and must be stored at controlled room temperature. The usual adult dosage can be found in the package insert. The medicine should be kept out of the reach of children. The package contains 100 unit dose blisters, and the manufacturer is Apotex Inc. The medication is distributed by Safecor Health, LLC in Woburn, MA, USA.*

This appears to be a table showing the number of subjects at risk and proportion with B for Aripiprazole and Placebo at different time intervals after randomization for a medical study. The numbers listed under "ARIPIPRAZOLE" and "PLACEBO" seem to represent the number of subjects still involved in the study at certain time intervals. The text seems to be incomplete, so it's possible that there may be additional information missing.*

This appears to be a chart or graph comparing the proportion of subjects experiencing relapse between a group taking a medication called Aripiprazole and a group taking placebo. The chart also includes the number of subjects at risk in each group and the number of days from randomization.*

This appears to be a chart or graph displaying the proportion of subjects with relapse over time for two treatments labeled "ARIPIPRAZOLE" and "PLACEBO". The graph shows the days from randomization on the x-axis and the proportion of subjects with relapse on the y-axis. The number of subjects at risk for each treatment is also displayed at various time points.*